Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
NCT05712161
Aortic Stenosis, Aortic Valve Calcification
Tucson, Arizona, United States
View Trial DetailsNCT Number: NCT05851209
Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.
Interested in participating?
Request Info18 year and older
All sexes
Observational
University-Hospital Bonn, Bonn, Germany
Early recognition and management of aortic stenosis (AS) are substantial to avoid life threatening events during the clinical course. Multi-factorial complex mechanisms including fibrosis, oxidative stress, inflammation, angiogenesis, osteogenic differentiation and the effect of genetic risk variants have been proposed to be involved mechanistically in the pathogenesis of degenerative AS. It is crucial to identify the potentially involved mechanisms of AS progression in order to 1) identify patients at risk for pronounced cardiac damage and adverse outcomes that might benefit from early aortic valve replacement and 2) to discover treatment options that might slow down progression and lower adverse clinical events.
The consortium´s work has revealed that various inflammatory events play a substantial role for the onset and progression of aortic valve calcification and stenosis in cell culture and small animal experiments We hypothesize that patients with and without rapid progress to severe aortic stenosis differ in terms of genetic, immunological and imaging parameters early in the disease course, and that these parameters can be combined to create strong and reliable predictors of disease progression. Hence, we plan to assess multiple morphological, functional, genetic and immunological readouts and investigate their capacity to predict disease progression in AS in a clinical observational cohort of 938 patients with moderate AS.
This project is a working package as part of TRR259, which is a collaborative project between the three universities: Bonn, Cologne and Düsseldorf.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 years
Prevalence (number of participants) measured by transthoracic echocardiography
Time frame: 5 years
Rate of patients (%) being hospitalized due to a progress of aortic stenois
Time frame: 5 years
Time frame: 5 years
Time frame: 5 years
Contact information is provided by the study sponsor or research team.
Lisa Dannenberg, MD
CONTACT
Tobias Zeus, MD
CONTACT
Heinrich-Heine University, Duesseldorf
Other
Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05712161
Aortic Stenosis, Aortic Valve Calcification
Tucson, Arizona, United States
View Trial DetailsNCT07620925
Aortic Stenosis, Aortic Valve Disease
Bologna, Italy
View Trial DetailsNCT04968509
Aortic Stenosis, Aortic Valve Disease
Beijing, Beijing Municipality, China
View Trial DetailsNCT06991517
Aortic Stenosis, Aortic Valve Disease
St Leonards, New South Wales, Australia
View Trial Details